Natco Pharma is the leader in the oncology segment and the market leader in sales. The management expects 20% growth in the oncology segment in the next 2-3 years. It is increasing its presence in the retail pharma space in the US and has acquired three stores in the US and are looking for more acquisitions. The company’s valuation are attractive and are trading at a PE of 5.2 time. It’s FY08 sales was seen at Rs 330 crore and profit at Rs 42 cr On Interlink Petroleum was allotted 2 blocks in